| | Study | CIMP panel markers | Notes |
| | Toyota et al. [7] | CDKN2A (p16), MINT1, MINT2, MINT12, MINT17, MINT25, MINT27, MINT31, MLH1, THBS1 | Pioneering work to identify markers that distinguish CIMP from age-related methylation | | Park et al. [31] | CDKN2A, MINT1, MINT2, MINT31, MLH1 | So-called “classic” or traditional panel | | Weisenberger et al. [13] | CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1 | “New” panel based on stepwise screen of 195 markers | | Ogino et al. [34] | CACNA1G, CDKN2A, CRABP1, MLH1, NEUROG1 | Selected markers to distinguish high-level from low-level methylation | | Shen et al. [33] | CIMP1: MINT1, MLH1, RIZ1, TIMP3, BRAF mutation; CIMP2: MINT2, MINT27, MINT31, Megalin, KRAS mutation | Examined 27 CpG sites, proposed optimal epigenetic and genetic markers to identify CIMP1, CIMP2, or CIMP- | | Tanaka et al. [35] | CACNA1G, CDKN2A, CHFR, CRABP1, HIC1, IGF2, IGFBP3, MGMT, MINT1, MINT31, NEUROG1, p14, RUNX3, SOCS1, WRN | Correlation structures of markers and CIMP differ by KRAS and BRAF status | | Ang et al. [36] | Total of 202 CpG sites differentially methylated between tumor and normal | Comprehensive DNA methylation profiling in 807 cancer genes | | Kaneda and Yagi [37] | Group 1: IGF2, LOX, MINT1, MINT2, MINT31, MLH1, RUNX3, SOCS1; Group 2: ADAMTS1, DUSP26, EDIL3, ELMO1, FBN2, HAND1, IGFBP3, NEUROG1, RASSF2, STOX2, THBD, UCHL1 | Comprehensive DNA epigenotyping of genomewide regions indentified two groups (high and intermediate to low methylation) |
|
|
